Centers of excellence conduct disease surveillance and real-world vaccine effectiveness studies evaluating vaccine-preventable diseases affecting adults

In January, Pfizer's Vaccines Division announced the launch of its Centers of Excellence Network, a global program of collaborations with academic institutions to conduct real-world epidemiologic research to accurately identify and measure the burden of specific vaccine-preventable diseases and potentially evaluate vaccine effectiveness affecting adults.

Pfizer Vaccines has designated the University of Louisville as its first Center of Excellence and is planning to establish a few additional centers for epidemiological research strategically located around the world in coming years.

“With strategically-located research centers, we anticipate being able to better define and understand the global disease burden in adults and vaccine effectiveness. This will help provide robust evidence to the national policymakers and health officials who develop recommendations for the use of vaccines in immunization programs worldwide,” said Luis Jodar, Chief Medical and Scientific Affairs Officer, Pfizer Vaccines.